Aminoindazole derivatives as medicaments and pharmaceutical compositions including them
申请人:Aventis Pharma S.A.
公开号:US07166629B2
公开(公告)日:2007-01-23
The present invention relates to novel derivatives of general formula (I)
in which
R3 is a (1–6C)alkyl, aryl, aryl(1–6C)alkyl, heteroaryl, heteroaryl(1–6C)alkyl, aryl or heteroaryl fused to a (1–10C)cycloalkyl, heterocycle, heterocycloalkyl, cycloalkyl, adamantyl, polycycloalkyl, alkenyl, alkynyl, CONR1R2, COOR1, SO2R1, C(═NH)R1 or C(═NH)NR1 radical;
R5 and R6 are, independently of one another, chosen from the following radicals: halogen, CN, NO2, NH2, OH, COOH, C(O)OR8, —O—C(O)R8, NR8R9, NHC(O)R8, C(O)NR8R9, NHC(S)R8, C(S)NR8R9, SR8, S(O)R8, SO2R8, NHSO2R8, SO2NR8R9, —O—SO2R8, —SO2—O—R8, trifluoromethyl, trifluoromethoxy, (1–6C)alkyl, (1–6C)alkoxy, aryl, aryl(1–6C)alkyl, heteroaryl, heteroaryl(1–6C)alkyl, heterocycle, cycloalkyl, alkenyl, alkynyl, adamantyl or polycycloalkyl.
本发明涉及一般式(I)的新衍
生物,其中R3是(1-6C)烷基,芳基,芳基(1-6C)烷基,杂环芳基,杂环芳基(1-6C)烷基,芳基或杂环芳基与(1-10C)环烷基,杂环,杂环环烷基,环烷基,
金刚烷基,多环环烷基,烯基,炔基,CONR1R2,COOR1,SO2R1,C(═NH)R1或C(═NH)NR1基团;R5和R6分别选自以下基团:卤素,CN,
NO2,NH2,OH,COOH,C(O)OR8,—O—C(O)R8,NR8R9,NHC(O)R8,C(O)NR8R9,NHC(S)R8,C(S)NR8R9,SR8,S(O)R8,SO2R8,NHSO2R8,SO2NR8R9,—O—SO2R8,—SO2—O—R8,三
氟甲基,三
氟甲氧基,(1-6C)烷基,(1-6C)烷氧基,芳基,芳基(1-6C)烷基,杂环芳基,杂环芳基(1-6C)烷基,杂环,环烷基,烯基,炔基,
金刚烷基或多环环烷基。